Lexaria Bioscience Corp. LXRP Archives - Page 8 of 27

ThursdayJul 18, 2019 2:39 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Consistently Outperforms Industry Standards

Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently reported that clinical lab tests conducted with live animals demonstrated that its new, enhanced version of DehydraTECH(TM) can deliver eight times more CBD into the blood and 19 times more CBD into the brain tissue than standard industry formulations (http://ibn.fm/5y9TR). An article discussing the company reads, “LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees. . . . In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137% more cannabidiol (CBD)…

ThursdayJul 11, 2019 9:39 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTC: LXRP) DehydraTECH to be Leveraged Through CBD License Agreement with Universal Hemp

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) today announced its entry into a definitive five-year agreement, via its subsidiary Lexaria Hemp Corp., to provide its patented DehydraTECH(TM) technology to Universal Hemp LLC. Under the agreement, Universal Hemp, a B2B manufacturer of high-performing hemp-derived bulk ingredients to the consumer packaged goods and nutraceutical industries, will utilize the technology in many CBD-based food ingredients to be produced and sold across the U.S. immediately, as well as in Canada when regulations permit. “We are very excited about signing this licensing agreement with Lexaria Bioscience to bring to…

WednesdayJul 10, 2019 10:52 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Partners with Nic’s Beverages in Definitive CBD Beverage License Agreement

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced its entry into a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, with Nic’s Beverages L.L.C. Under the agreement, Lexaria will provide its patented DehydraTECH(TM) technology for use in Nic’s CBD-based beverages to be produced and sold throughout the United States. According to the update, Nic’s Beverages will initially begin production of ready-to-drink cold brew coffees enhanced with CBD from multi spectrum hemp oil. “We are currently in discussions with major wholesale houses and are looking to be in the market by the…

MondayJul 08, 2019 10:08 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Leading the Way in Effective Cannabis Treatment

Lexaria developed and out-licenses DehydraTECH to create new (and improve existing) drug-delivery products The company is credited with leading the way forward in discovering new ways to effectively deliver CBD into the human body Lexaria is helping firms meet supply and demand requirements by creating products that offer lower dosing with higher absorption Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is known for its innovative delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. The company developed drug-delivery platform DehydraTECH and out-licenses the platform to create new (and improve existing) orally ingested…

TuesdayJul 02, 2019 10:20 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Enhanced DehydraTECH Delivers More CBD into the Body

The new version of the DehydraTECH delivery platform is suitable for use in pills, capsules and tablets for the pharmaceutical, medical and supplement markets DehydraTECH has demonstrated that it can deliver eight times more CBD into the blood than standard industry formulations Animal testing shows that combining DehydraTECH with a nanoemulsion formulation greatly assists delivery of cannabinoids and nicotine across the blood-brain barrier Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) new enhanced version of its patented delivery technology, DehydraTECH, has demonstrated that it can deliver eight-times more CBD into the blood and 19-times more CBD into the brain tissue than…

MondayJun 24, 2019 9:45 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Releases 2019 Annual and Special Meeting Results

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) on Friday announced the results of its 2019 annual and special meeting. Held on June 20, 2019, there were 43,217,711 company shares represented in person or by proxy at the meeting, constituting 55.1 percent of Lexaria's issued share capital as of May 3, 2019, the record date of the meeting. The matters voted upon included board member elections, the appointment of Davidson & Company LLP as auditors, approval of the company’s equity incentive plan and executive compensation, and the timeline for approval of executive compensation going…

FridayJun 21, 2019 2:13 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Continues to Demonstrate Effectiveness in Lab Testing

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) patented drug-delivery platform, DehydraTECH, has exhibited continued success in recent animal lab tests by delivering cannabinoids to the bloodstream faster than conventional cannabinoid formulations (http://ibn.fm/pYSzq). A recent article discussing the company reads, “Lab tests and actual licensed use in the cannabis industry have proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is able to deliver cannabinoids faster than formulations with medium-chain triglyceride (“MCT”) oils, such as coconut oil. DehydraTECH also offers the most advanced flavor and aroma-profile masking techniques in the industry. The groundbreaking technology could negate the need for artificial chemical masking agents…

ThursdayJun 13, 2019 2:49 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Technology Credited as Major Factor in 1906 Edibles Appeal

Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM) is credited as part of the major appeal of Nuka Enterprises LLC’s 1906 cannabis edibles. A recent article quotes Nuka CEO and co-founder Peter Barsoom, where he states, “As the fastest-growing edibles brand in Colorado, we believe a huge part of our consumer appeal is because of this fast-acting technology. We look forward to continuing to innovate alongside Lexaria, whose technology is the best in the industry.” To view the full article, visit http://ibn.fm/fRoqy About Lexaria Bioscience Corp. Lexaria Bioscience has developed and out-licenses its disruptive…

ThursdayJun 06, 2019 11:53 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers 475% More CBD to the Bloodstream

LXRP’s DehydraTECH has been shown to outperform conventional cannabis formulations and deliver 475 percent more CBD to the bloodstream in the first 15 minutes Compared to other industry formulations, DehydraTECH delivered cannabinoids quicker at industry-leading volumes A DehydraTECH formulation achieved a 319 percent higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH delivery technology has demonstrated in animal lab tests that it can deliver cannabinoids to the bloodstream more quickly than conventional cannabinoid formulations (http://ibn.fm/pYSzq). At 15 minutes into the test, the DehydraTECH formulation achieved a blood…

WednesdayJun 05, 2019 10:20 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Opportunities for 1906 Edibles

LXRP has expanded its cannabis product relationship with Nuka Enterprises’ 1906 brand DehydraTECH enables 1906 chocolates to deliver on both function and flavor The company is expecting a tenfold increase in sales with expansion to legal markets Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), the developer and out-licenser for the disruptive and cost-effective DehydraTECH, recently announced that it has expanded its cannabis product relationship with Nuka Enterprises LLC, maker of 1906 cannabis edibles for high-functioning adults (http://ibn.fm/d1Uuv). Since its beginnings in 2016, 1906 chocolates have benefited from DehydraTECH technology. In three short years, Nuka has become Colorado’s fastest-growing edibles company, and…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP